Tubular proteinuria as an indicator for elevated cardiovascular risk
AssigneeSanofi-Aventis Deutschland GmbH
InventorJoachim SCHRADER
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of an ACE inhibitor or an angiotensin receptor antagonist for the preparation of a pharmaceutical composition for reducing tubular proteinuria oral/or α1-microglubulin in a non-diabetic human individual for reducing the risk of a cardiovascular event.
Claims5
Use of an ACE inhibitor or an angiotensin receptor antagonist for the preparation of a pharmaceutical composition for reducing tubular proteinuria and/or α1-microglobulin in a non-diabetic human individual for reducing the risk of a cardiovascular event.
An in vitro diagnostic method for the assessment of the risk of a human individual to suffer from a cardiovascular disease or a cardiovascular event comprising determining the level of urinary β-microglobulin or other tubular proteins and α1-microglobulin.
Dependencies are inferred from the claim text.